A North Texas woman says a new medication treating postpartum depression helped her get through the hardest year of her life.

A month has gone by since the last earnings report for Sage Therapeutics, Inc. (SAGE). Shares have lost about 11.1% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Last Friday, Sage Therapeutics announced the FDA rejected its major depressive disorder drug candidate, zuranolone. In response, the drugmaker's shares cratered Monday. This hefty sell-off may ...

Since the past month, Sage Therapeutics’ SAGE shares have lost 45.6% against the industry’s 0.1% growth. Zacks Investment Research Image Source: Zacks Investment Research This downside is ...

Sage Therapeutics (NASDAQ:SAGE) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Sage ...

Chief Executive Officer at Sage Therapeutics. “Beyond our ongoing commercialization efforts for ZURZUVAE, we look forward to delivering on multiple anticipated catalysts in 2024, including ...

Good afternoon. Welcome to Sage Therapeutics First Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being webcast live on the Investors and Media section of ...

Oct 8 (Reuters) - Sage Therapeutics (SAGE.O), opens new tab said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main ...

Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading for the exits along with a swath of the company's leadership.

SAGE Therapeutics (SAGE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from H.C. Wainwright reiterated a Hold rating on the ...